Key result
Post-valve antithrombotics depend on prosthesis type, requiring warfarin for mechanical valves and aspirin monotherapy for TAVI.
Why the study?
As the population with intracardiac valve prostheses grows, uncertainty remains regarding antithrombotic therapy strategies, such as anticoagulation versus antiplatelet therapy for tissue prostheses, repaired valves, or transcatheter interventions.
This review summarizes current evidence and guidance for antithrombotic management across different types of heart valve prostheses and interventions.
No takes yet. Share an insight, caveat, or question.
May guide individualized antithrombotic choices by valve type and risk; leaves open need for updated RCTs in TAVI.
Cheng et al. (2023) conducted a review in Heart valve disease with intracardiac valve prostheses. Antithrombotic therapy was evaluated. Antithrombotic management after heart valve intervention depends on prosthesis type and patient risk, with mechanical valves requiring warfarin and TAVI patients often maintained on aspirin monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: